Effect of nitric oxide on the somatostatinergic system in the rat exocrine pancreas  by Rodrı́guez-Martı́n, E et al.
E¡ect of nitric oxide on the somatostatinergic system in the rat exocrine
pancreas
E. Rodr|¤guez-Mart|¤n, G. Mun‹oz-Acedo, L. Puebla, E. Arilla *
Departamento de Bioqu|¤mica y Biolog|¤a Molecular, Facultad de Medicina, Universidad de Alcala¤, E-28871, Alcala¤ de Henares,
Madrid, Spain
Received 13 October 1998; received in revised form 25 February 1999; accepted 10 March 1999
Abstract
Nitric oxide (NO) and somatostatin (SS) are two important mediators of the exocrine and endocrine pancreas, exerting
opposite effects on this organ. There is strong evidence suggesting an interaction between pancreatic NO and SS. The aim of
this study was to determine whether L-arginine (L-Arg), the substrate for NO synthase (NOS), and Ng-nitro-L-arginine
methyl ester (L-NAME), a NOS inhibitor, regulate pancreatic somatostatin-like immunoreactivity (SSLI) content and the SS
mechanism of action in pancreatic acinar cell membranes. L-Arg (150 mg/kg, intraperitoneally (i.p.)), L-NAME (50 mg/kg,
i.p.) or L-NAME plus L-Arg were injected twice daily at 8 h intervals for 8 days. L-Arg decreased pancreatic SSLI content as
well as the number of SS receptors in pancreatic acinar cell membranes whereas L-NAME increased both parameters. The
stable SS analogue SMS 201-995 induced a significantly lower inhibition of forskolin-stimulated adenylyl cyclase activity in
pancreatic acinar cell membranes from L-Arg-treated rats whereas an increased inhibition was observed in pancreatic acinar
membranes from L-NAME-treated rats. These results indicate that the NO system may contribute to the regulation of the
pancreatic somatostatinergic system. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitric oxide (NO) and somatostatin (SS) are two
important mediators of the exocrine and endocrine
pancreas. The gaseous compound NO has recently
been discovered to be an important intra- and inter-
cellular messenger in a number of organ systems [1].
It is synthesized from molecular O2 and the guanidi-
no group of L-arginine (L-Arg) by NO synthase
(NOS) [1]. NO has been puri¢ed, characterized and
cloned from brain, macrophages and endothelial cells
[1^3]. It binds to iron in the heme group of soluble
guanylate cyclase, stimulating the formation of gua-
nosine 3P-5P-cyclic monophosphate (cGMP) [2]. Re-
cent studies have suggested that NO may be an im-
portant neurotransmitter in the pancreas. NOS has
been located in the pancreas, not only in ganglia or
nerve terminals innervating acinar tissue and islets,
but also in A and B cells [4^6]. In addition, puri¢ca-
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tion of NOS from isolated pancreatic acini demon-
strates the presence of this enzyme in acinar cells and
supports a direct role for NO as a regulator of pan-
creatic exocrine function at the level of the acinar
cells [5,7]. In this regard, L-Arg has been shown to
induce an increase in amylase [5] and insulin release
[8^10] in the rat pancreas. Inhibitors of the enzy-
matic conversion of L-Arg to NO inhibited insulin
secretion induced by L-Arg in the presence of D-glu-
cose [8]. Colocalization of neuronal NOS and SS has
also been found in the pancreatic islets, where strong
NOS immunoreactivity appeared in scattered cells
which were peripheral in rat and mouse islets and
more randomly distributed in human [11,12].
On the other hand, SS is a tetradecapeptide ini-
tially isolated from the hypothalamus as an inhibitor
of pituitary growth hormone secretion [13]. SS acts
as a negative regulator of pancreatic exocrine and
endocrine secretions in both pancreas and gut. It
has been previously reported that pancreatic acini
possess speci¢c binding sites for SS, the binding of
which results in the triggering of some biological
actions of SS in the pancreas [14,15]. In pancreatic
acinar cells, SS receptors are negatively coupled to
the adenylyl cyclase (AC) enzyme system via a gua-
nine nucleotide-binding inhibitory protein (Gi-pro-
tein) [16], leading to a decrease in adenosine 3P-5P
cyclic monophosphate (cAMP) levels. Among its var-
ious inhibitory functions, SS decreases pancreatic
amylase release [17]. An imbalance between NO
and SS may contribute to alterations in pancreatic
acinar cell secretion. The aim of this study was to
determine whether NO regulates the SS receptor-ef-
fector system in rat pancreatic acinar membranes. In
this regard, we evaluated the e¡ects of the NOS sub-
strate L-Arg and the NOS inhibitor Ng-L-arginine
methyl ester (L-NAME) on the somatostatin recep-
tors, SS-mediated inhibition of AC activity in rat
pancreatic acinar membranes. Pancreatic somatosta-
tin-like immunoreactivity (SSLI) content was also
determined.
2. Materials and methods
2.1. Materials
The stable SS analogue SMS 201-995 and its tyro-
sine analogue Tyr3-SMS or SMS 204-090 were kindly
donated by Sandoz (Basel, Switzerland). Collagenase
(from Clostridium histolyticum) was obtained from
Serva Fine Chemicals (Tebu, France). L-NAME,
L-Arg, bacitracin, phenylmethylsulfonyl£uoride
(PMSF), guanosine triphosphate (GTP), 3-isobutyl-
1-methylxanthine (IBMX) and bovine serum albumin
(BSA) were purchased from Sigma (St. Louis, MO,
USA). Carrier-free Na[125I] (IMS 300, 100 mCi/ml)
and the rabbit antibody used in the radioimmuno-
assay technique were purchased from the Radio-
chemical Center (Amersham, UK). This antiserum
was raised in rabbits against SS-14 conjugated to
BSA and is speci¢c for SS, but since SS-14 consti-
tutes the C-terminal portion of both SS-25 and SS-
28, the antiserum does not distinguish between these
three forms. In the rat pancreas, SS-14 is the pre-
dominant molecular species, constituting 95% of to-
tal SS, whereas SS-28 seems to comprise less than 5%
of the immunoreactivity [18]. All other agents were
of the highest purity commercially available.
2.2. Experimental animals
The animal experiments performed in the present
study were conducted under the guidelines of the
Animal Care Committee of Alcala¤ University and
the experimental protocols have been approved.
Male Wistar rats weighing 200^250 g were injected
intraperitoneally (i.p.) twice daily at 8 h intervals for
8 days with the following agents: L-NAME (50 mg/
kg) [19,20], L-Arg (150 mg/kg) [21^23], L-NAME plus
L-Arg or saline in a volume (400 Wl) equal to that
used for the other compounds. The animals were
sacri¢ced 14 h after the last injection and the pan-
creas was removed and trimmed free of fat, connec-
tive tissues and lymph nodes.
2.3. Preparation of rat pancreatic acinar membranes
Dispersed pancreatic acini were obtained from
male Wistar rats after enzymatic degradation of the
organ with 0.2 units of collagenase/ml in an oxygen-
ated Krebs-Ringer medium as described by Amster-
dam et al. [24]. After thorough washing by sedimen-
tation, acini were transferred to 0.3 M sucrose and
homogenized at 4‡C using of a Potter homogenizer
following the method of Meldolesi et al. [25]. After
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sedimentation at 1500Ug for 12 min, the homogen-
ized membranes were resuspended in 1.56 M sucrose.
This suspension was overlaid with 0.3 M sucrose and
centrifuged at 105 000Ug for 150 min. The plasma
membrane-enriched fraction collected from the inter-
phase was diluted with distilled water and centri-
fuged at 15 000Ug for 30 min. The supernatant
was discarded and the pellet was resuspended in
50 mM Tris-HCl pH 7.4, 0.01 mg/ml bacitracin,
0.2 mM CaCl2 and stored at 370‡C. An aliquot
was taken for protein determination by the method
of Lowry et al. [26].
2.4. [125I-Tyr3]SMS binding
[125I-Tyr3]SMS binding was assayed on pancreatic
acinar membranes from Wistar rats by a modi¢ed
method [27]. The stable SS-14 analogue SMS 204-
090 or [Tyr3]SMS, which shares the biological prop-
erties of SMS 201-995 and has proven valuable in the
characterization of SS-14 binding to receptors in rat
pancreatic acinar [28] and brain [29] membranes, was
radioiodinated by the chloramine-T method and pu-
ri¢ed by HPLC according to Antoniotti et al. [30].
Its speci¢c radioactivity was found to be 900 Ci/
mmol.
Binding of [125I-Tyr3]SMS to pancreatic acinar
membranes was carried out in a total volume of
250 Wl in 50 mM Tris-HCl bu¡er (pH 7.4) containing
0.5 mM MgCl2, 3 mM NaCl, 0.2 mM CaCl2, 0.2%
(w/v) BSA, 0.5 mg/ml bacitracin and 0.3 mg/ml soy-
bean trypsin inhibitor (binding bu¡er). Plasma mem-
branes (36 Wg protein/ml) were incubated for 90 min
at 20‡C with 35 pM [125I-Tyr3]SMS in the absence or
presence of 0.001^10 nM unlabeled SMS 201-995.
Bound and free ligand were separated by centrifuga-
tion at 11 000Ug for 4 min at 4‡C in a microcentri-
fuge. Radioactivity in the pellet was measured with a
gamma scintillation counter. Non-speci¢c binding
was estimated as membrane-associated radioactivity
in the presence of 1 WM SMS and speci¢c binding
was calculated as the di¡erence between total and
non-speci¢c membrane-associated radioactivity.
2.5. Adenylate cyclase assay
Adenylate cyclase activity was measured as previ-
ously reported [31] with minor modi¢cations. Brie£y,
rat pancreatic acinar membranes (0.12 mg protein/
ml) were incubated with 1.5 mM ATP, 5 mM
MgSO4, 1 mM GTP and an ATP-regenerating sys-
tem (7.5 mg/ml creatine phosphate and 1 mg/ml cre-
atine kinase), 1 mM IBMX, 0.1 mM PMSF, 1 mg/ml
bacitracin, 1 mM EDTA, and tested substances (1039
M SMS 201-995 or 1035 M forskolin (FK)) in 0.1 ml
of 0.025 M triethanolamine-HCl bu¡er (pH 7.4).
After a 30 min incubation at 30‡C, the reaction
was stopped by heating the mixture for 3 min. After
cooling, 0.2 ml of an alumina slurry (0.75 g/ml in
triethanolamine-HCl bu¡er, pH 7.4) was added and
the suspension centrifuged. The supernatant was tak-
en for assay of cyclic AMP by the method of Gilman
[32].
2.6. Tissue extraction and SS radioimmunoassay
[Tyr11]SS was radioiodinated by chloramine-T io-
dination according to the method of Greenwood [33].
Separation of iodinated SS from unincorporated io-
dine was carried out on a Sephadex G-25 (¢ne) col-
umn equilibrated and eluted with 0.1 M acetic acid in
BSA (0.1% w/v). Its speci¢c activity was found to be
900 Ci/mmol.
For SSLI measurement, the pancreas was rapidly
homogenized in 1 ml of 2 M acetic acid using a
Brinkman polytron (setting 5, 30 s). The extracts
were boiled for 5 min, cooled in an ice-chilled water
bath, and aliquots (100 Wl) were removed for protein
determination [26]. The homogenates were subse-
quently centrifuged at 15 000Ug for 15 min at 4‡C
and the supernatant was neutralized with 2 M
NaOH. The extracts were stored at 370‡C until as-
say. The SS concentration was determined in tissue
extracts by a modi¢ed radioimmunoassay method
[34], with a sensitivity limit of 10 pg/ml. Incubation
tubes prepared in duplicate contained 100 Wl samples
of tissue extracts or standard solutions of 0^500 pg
of cyclic SS-14 diluted in phosphate bu¡er (0.05 M,
pH 7.2 containing 0.3% BSA, 0.01 M EDTA), 200 Wl
of appropriately diluted anti-SS serum and 100 Wl of
freshly prepared [125I-Tyr11]SS diluted in bu¡er to
give 6000 cpm (equivalent to 5^10 pg), in a ¢nal
volume of 0.8 ml. All reagents as well as the assay
tubes were kept chilled on ice before their incubation
at 4‡C for 48 h. Bound hormone was separated from
free hormone by the addition of 1 ml of dextran-
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coated charcoal (dextran T-70, 0.2% w/v, Pharmacia,
Uppsala, Sweden; charcoal: Norit A, 2% w/v, Serva,
Feinbiochemica, Heidelberg, Germany). Serial dilu-
tion curves for the samples were parallel to the
standard curve. The intra- and inter-assay variation
coe⁄cients were 6.0 and 8.8% respectively.
2.7. Data analysis
The LIGAND computer program [35] was used to
analyze the binding data. The use of this program
made it possible to select the models of receptors
which best ¢t a given set of binding data. The
same program was also used to present data in the
form of Scatchard plots [36] and to compute the
values for receptor a⁄nity (Kd) and density (Bmax)
that best ¢t the sets of binding data for each rat.
Statistical comparisons of all the data were analyzed
by ANOVA and the Newman-Keuls t-test. Means
among groups were considered signi¢cantly di¡erent
when the P value was less than 0.05. Each individual
experiment was performed in duplicate.
3. Results
3.1. Pancreatic somatostatin-like immunoreactivity
content
The administration of L-Arg induced a signi¢cant
decrease in SSLI content in the rat pancreas, whereas
L-NAME or L-NAME plus L-Arg increased its con-
tent (Table 1).
3.2. [I125-Tyr3]SMS binding
Speci¢c [I125-Tyr3]SMS binding to pancreatic aci-
nar membranes changed linearly with protein con-
centration and was time-dependent in all experimen-
tal groups. An apparent equilibrium was observed
between 60 and 120 min at 20‡C (data not shown).
All subsequent binding experiments were therefore
conducted at 20‡C for 90 min.
Speci¢c [125I-Tyr3]SMS binding to rat pancreatic
acinar cell membranes was signi¢cantly decreased
in L-Arg-treated rats as compared to control rats
(Fig. 1, left panel, Table 2). This decrease was due
to a decrease in the maximal number of SS receptors
with no changes in the dissociation constant, as
revealed by Scatchard plots of the binding data
(Fig. 1, right panel, Table 2). The administration of
L-NAME+L-Arg reverted the number of SS receptors
to control values whereas L-NAME alone increased
the SS receptor density. The addition of 1034^10311
M of L-Arg and/or L-NAME to the incubation me-
dium changed neither the number nor the a⁄nity of
the SS receptors in pancreatic acinar cell membranes
from normal rats (data not shown).
Table 1
Pancreatic somatostatin-like immunoreactive (SSLI) content
from rats treated for 8 days with saline, L-Arg, L-NAME or
L-NAME plus L-Arg
Group SSLI
Saline 4.48 þ 0.38
L-Arg 3.6 þ 0.32*
L-NAME 9.8 þ 0.83***
L-NAME+L-Arg 7.69 þ 10.4*
Units for SSLI are ng of SS per mg pf protein. Values are the
means þ S.E.M. of the data from ¢ve rats in each group. Deter-
minations were made in duplicate for each experiment. Statisti-
cal comparison versus controls: *P6 0.05, ***P6 0.001.
Table 2
Equilibrium parameters for [125I-Tyr3]SMS binding to pancreat-
ic acinar membranes from rats treated for 8 days with saline,
L-Arg, L-NAME or L-NAME plus L-Arg
Groups SS receptors
Saline
Bmax 4739 þ 143
Kd 0.62 þ 0.03
L-Arg
Bmax 3718 þ 152**
Kd 0.53 þ 0.05
L-NAME
Bmax 6254 þ 298**
Kd 0.57 þ 0.06
L-NAME+L-Arg
Bmax 4374 þ 132
Kd 0.50 þ 0.07
Binding parameters were calculated from Scatchard plots by
linear regression. Units for Kd are nM and units for Bmax are
femtomoles of SMS bound per mg of protein. Values are the
means þ S.E.M. of the data from ¢ve rats in each group. Deter-
minations were made in duplicate for each experiment. Statisti-
cal comparison versus controls: **P6 0.01.
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3.3. Adenylyl cyclase assay
The functional coupling of the SS receptors to the
AC system was also investigated. To study the SMS-
modulated AC activity, pancreatic acinar cell mem-
branes were incubated with SMS (1039 M) either
alone or together with FK (1035 M), a direct AC
activator. As shown in Table 3, no signi¢cant di¡er-
ences were seen for either basal or FK-stimulated AC
enzyme activity in pancreatic acinar cell membranes
from control, L-Arg- and/or L-NAME-treated rats.
The e¡ect of SMS 201-995 on FK-stimulated AC
activity was markedly decreased in pancreatic acinar
membranes from L-Arg-treated rats as compared to
control animals (Table 3). This e¡ect, however, was
increased in pancreatic acinar membranes from L-
NAME-treated rats, whereas the administration of
L-NAME+L-Arg reverted this e¡ect to control val-
ues.
4. Discussion
The present study shows that L-Arg, a substrate
for NO production, decreases pancreatic SSLI levels
and the number of speci¢c SS receptors, without al-
tering their a⁄nity, in rat pancreatic acinar cell mem-
branes. In addition, L-Arg induces a decrease in the
inhibitory e¡ect of SMS 201-995 on AC activity in
these membranes.
The L-Arg concentration used in the present study
was in agreement with the dose reported by others
and has been demonstrated to induce NO production
[21^23]. The choice of L-NAME was dictated by its
previous characterization as a NOS inhibitor [37^39].
In addition, Bannerman et al. [20] and Dwyer et al.
[19] have shown that the level of NOS inhibition
actually increases with repeated injections.
The pancreatic SSLI levels in the control rats were
similar to those previously reported by others [14,40].
L-Arg has been described to produce a dose-related
increase of SS release from the isolated perfused rat
pancreas [41]. On the other hand, the intracellular
concentration of Ca2, which is known to be a po-
tent stimulator of SS secretion [42,43], is increased by
NO. Therefore, it is possible that the increase of SS
release by the D-cells of the islets of Langerhans
could lead to a decrease of pancreatic SSLI levels
found in L-Arg-treated rats.
Although ¢ve SS receptors subtypes have thus far
been cloned [44], the rat exocrine pancreas appears to
express only SS receptor subtype 2 (sst2) [45]. There-
fore, the present results suggest that the changes in
the SS receptor number observed after L-Arg or
Table 3
The e¡ect of SMS 201-995 (1039 M) and FK (1035 M) on AC activity (pmol cAMP/min/mg protein) in pancreatic acinar membranes
from rats treated for 8 days with saline, L-Arg, L-NAME or L-NAME plus L-Arg
Control L-Arg L-NAME L-NAME+L-Arg
Basal activity 15.2 þ 1.2 14.7 þ 1.0 14.0 þ 1.1 15.4 þ 1.3
+1039 M SMS 12.1 þ 1.0 11.3 þ 0.7 11.6 þ 0.9 12.0 þ 0.8
+1035 M FK 22.3 þ 0.7. 22.5 þ 0.6 21.0 þ 1.0 21.8 þ 1.1
1035 M FK+1039 M SMS 13.9 þ 0.2 17.5 þ 0.4*** 9.2 þ 0.1*** 13.2 þ 0.3
% SMS inhibition of FK-stimulated AC activity 37.7 þ 3.5 22.2 þ 1.8** 56.2 þ 2.8** 39.4 þ 2.2
Experiments were performed as described in Section 2. Values represent the means þ S.E.M. of ¢ve separate experiments, each per-
formed in duplicate. Statistical comparison versus control: **P6 0.01, ***P6 0.001.
Fig. 1. (Left panel) Competitive inhibition of speci¢c 125I-Tyr3-
SMS (SMS 204-090) binding to rat pancreatic acinar mem-
branes by unlabeled SMS 201-995. Points correspond to control
rats (a), rats treated for 8 days with L-Arg (R), L-NAME (b)
or L-NAME combined with L-Arg (O). Each point is the mean
of ¢ve separate experiments, each performed in duplicate.
(Right panel) Scatchard analysis of the same data. The kinetic
constants calculated by Scatchard analysis are given in Table 2.
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L-NAME administration could result, at least in
part, from changes of the sst2 subtype. The binding
parameters of the SS receptors in the control rats
were similar to those previously reported by others
[14,15].
The changes in [125I-Tyr3]SMS binding were not a
result of a direct e¡ect of L-Arg or L-NAME on the
SS receptors, since no change in tracer binding was
detected following incubation of fresh pancreatic aci-
nar cell membranes with L-Arg or L-NAME. In ad-
dition, NO seems to mediate the action of L-Arg on
the SS receptor-e¡ector system because the changes
in SS binding and the inhibitory e¡ect of this neuro-
peptide on AC activity induced by L-Arg were pre-
vented by pretreatment with the NOS inhibitor
L-NAME which, when administered alone, increased
both parameters.
At present, we can only speculate on the identity
of the postreceptor mechanisms responsible for the
regulation of the SS receptors by NO in rat pancre-
atic acinar cell membranes. Although most of the
NO actions have been reported to be mediated by
elevation of cGMP synthesis through activation of
soluble guanylate cyclase [1], cGMP has been shown
to have no e¡ect on SS binding [46]. Recently, NO
has been shown to be involved in Ca2 transport in
pancreatic acinar cells [42,43]. Willmott et al. [43]
suggest an action of NO in mobilizing intracellular
Ca2 from microsomal stores via a signaling path-
way involving cGMP and cyclic adenosine diphos-
phate ribose (cADP). As reported previously, the ac-
tivation of Ca2-activated phospholipid-dependent
protein kinase C (PKC) and intracellular Ca2 mo-
bilization can inhibit the binding of SS to its recep-
tors [47]. Therefore, it is possible that the increase of
intracellular Ca2 induced by endogenous NO could
decrease the number of SS receptors in pancreatic
acinar cell membranes.
On the other hand, pancreatic acinar cells, which
do not synthesize SS but possess functional SS recep-
tors [48], may respond to SS produced in the pan-
creas by the D-cells in the islets of Langerhans as
well as to circulating SS. Therefore, it is possible
that an increased pancreatic SS release induced by
L-Arg could cause a decrease in the number of SS
receptors in pancreatic acinar cell membranes.
SMS 201-995 did not modify basal AC activity
and was a partial antagonist of FK-stimulated pan-
creatic AC activity in agreement with other authors
[49]. The ability of SMS 201-995 to inhibit FK-
stimulated AC was decreased in pancreatic acinar
membranes from L-Arg-treated animals when com-
pared with controls. However, this does not appear
to be due to any defect in the catalytic subunit of AC
itself. Indeed, similar levels of activities were noted in
membranes from both control and L-Arg-treated an-
imals when the enzyme was stimulated directly by the
diterpene FK. In this regard, it has been recently
reported that NO and L-NAME do not modify basal
cAMP levels nor that stimulated by human chorionic
gonadotrophin hormone (hCG) in the MA-10 mur-
ine Leydig tumor cell line [50] and mouse brain [51],
respectively.
The physiological signi¢cance of the L-Arg-in-
duced down-regulation of the SS receptor-e¡ector
system is presently unknown. NO has been demon-
strated to increase amylase release [5], whereas SS
has been shown to decrease it [52]. In the present
study we have demonstrated that L-Arg, the sub-
strate of NOS, induces a decrease in the number of
SS receptors and in SMS-mediated inhibition of AC
activity. Therefore, it is possible the increase of amy-
lase secretion induced by NO might be due to this
L-Arg-induced decrease of the somatostatinergic sys-
tem. Moreover, these results suggest that the reduced
ability of SMS to inhibit AC activity is most prob-
ably due to the decrease in the number of SS recep-
tors alone.
On the other hand, we have shown that L-Arg
reduces SSLI content in the pancreas. It is well es-
tablished that SS inhibits insulin secretion [53]. NO,
however, has a stimulatory e¡ect on insulin secretion
[8^10]. Since L-Arg is the substrate for NO produc-
tion, it is tempting to speculate that the decrease of
SSLI caused by L-Arg is responsible for the NO-
mediated increase of insulin release.
Altogether, these results indicate that the NO sys-
tem may contribute to the regulation of the pancre-
atic somatostatinergic system.
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